Protein fingerprint may predict ovarian cancer relapse
NCT ID NCT00086567
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This study aimed to create a blood test that could predict when ovarian, peritoneal, or fallopian tube cancer might come back. Researchers looked for specific protein patterns, called a 'fingerprint,' in the blood of 119 women whose cancer was in remission. Participants had regular check-ups and blood draws over time to track their health and any signs of relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048-1804, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Evanston Northwestern University Hospital
Evanston, Illinois, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Massachusetts General Hospital, Dana Farber
Boston, Massachusetts, 02114, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
New York University School of Medicine
New York, New York, 10016, United States
-
Pacific Ovarian Cancer Research Consortium at FHCRC
Seattle, Washington, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Washington/Fred Hutchinson Cancer Research Center
Seattle, Washington, 28104, United States
Conditions
Explore the condition pages connected to this study.